PEG-PBAE Copolymers for Stable Gene Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current compositions for delivering therapeutic cargo to specific targets, such as cancer cells, face challenges in improving efficacy in vivo, reducing non-specific clearance in the blood, and minimizing protein adsorption to particles.
Innovation Solution
Development of polyethylene glycol (PEG)-b-poly(β-amino ester) (PBAE) co-polymers that form stable particles for drug and gene delivery, including DNA and siRNA, through a novel synthesis scheme, which involves conjugating PEG to PBAE polymers to enhance stability and reduce cytotoxicity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If non-PEGylated PBAE polymers are used for gene delivery, then transfection efficiency is achieved, but cytotoxicity increases and particle stability decreases
Solution Approach 1:
The patent applies composite materials by creating PEG-PBAE copolymers that combine polyethylene glycol (PEG) blocks with poly(β-amino ester) (PBAE) blocks. This composite structure integrates the stability and biocompatibility benefits of PEG with the gene delivery capabilities of PBAE, resolving the contradiction between particle stability and cytotoxicity. The PEG blocks provide steric stabilization and reduce cytotoxicity, while the PBAE blocks maintain transfection efficiency.
Solution Approach 2:
The patent applies local quality by functionalizing specific regions of the polymer structure with PEG groups at controlled ratios (1-50 mol%). This localized modification allows different parts of the polymer to perform different functions: PEG-rich regions provide stability and reduce toxicity, while PBAE-rich regions maintain gene delivery capability. The local composition can be tuned to optimize the balance between stability and cytotoxicity.
2Reliability
If PEG is conjugated to PBAE polymers, then cytotoxicity is reduced and stability is improved, but transfection efficiency may decrease
Solution Approach 1:
The patent applies parameter changes by systematically varying the PEG content (1-50 mol%), PEG block length, and PBAE block length to optimize the balance between stability and transfection efficiency. By adjusting these parameters, the patent demonstrates that transfection efficiency can be maintained or even enhanced while achieving improved stability and reduced cytotoxicity, depending on the specific application requirements.
Solution Approach 2:
The patent applies dynamics by creating polymers with tunable properties that can adapt to different delivery requirements. The dynamic balance between PEG and PBAE components allows the system to be optimized for specific applications - higher PEG content for stability-critical applications, lower PEG content for transfection-critical applications. This dynamic tunability resolves the contradiction by allowing optimization based on specific needs.
3Adaptability or versatility
If amphiphilic block copolymers are used, then drug delivery capability is enhanced, but protein adsorption to particles increases
Solution Approach 1:
The patent applies the intermediary principle by using PEG blocks as a protective layer between the hydrophobic drug cargo and the aqueous biological environment. The PEG chains extend from the particle surface, creating a steric barrier that prevents protein adsorption while allowing the amphiphilic structure to maintain its drug delivery capability. This intermediary PEG layer resolves the contradiction by shielding the particle from harmful protein interactions.
Data Source
AI summary
Polyethylene glycol (PEG)-b-poly(β-amino ester) (PBAE) co-polymers (PEG-PBAE) and blends of PEG-PBAEs and PBAEs and their use for delivering drugs, genes, and other pharmaceutical or therapeutic agents safely and effectively to different sites in the body and to different cells, such as cancer cells, are disclosed.